Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom

Contributed by: Business Wire

Logo

Tags

Science

Neurology

Biotechnology

Research

Pharmaceutical

Health

FDA

Clinical Trials

CORRECTION Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom

More Like This

Bial Launches Education and Awareness Campaign for World Parkinson’s Day

PR Newswire associated0

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

PR Newswire associated0

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Key Milestone in ACTIVATE Phase 2 Clinical Trial of BIA 28-6156

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease

PR Newswire associated0

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences